«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2015年第6期

页码:

720-724

栏目:

综述

出版日期:

2015-07-15

文章信息/Info

Title:

Review of progression in diagnosis and treatment of heart failure with preserved ejection fraction

作者:

汪小素; 宁晓暄

（第四军医大学西京医院老年病科，陕西 西安 710032）

Author(s):

WANG Xiao-su;  NING Xiao-xuan

(Department of Geriatrics, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)

关键词:

心力衰竭; 左室射血分数保留; 舒张性心衰

Keywords:

heart failure;  preserved left ventricular ejection fraction;  diastolic heart failure

分类号:

R541.6

DOI:

-

文献标识码:

A

摘要:

左心室射血分数(LVEF)保留的心力衰竭（HFPEF）旧称舒张功能不全的心力衰竭或收缩功能正常的心力衰竭，是一种日益流行的健康问题，相对与LVEF降低的心力衰竭（HFREF）而言，其特征是LVEF正常或接近正常，但有心力衰竭的临床表现。2013 ACCF/AHA心力衰竭管理指南［1］大大提高了对HFPEF的重视程度，将LVEF≥50%定义为 HFPEF。临床上该型患者的发病率逐渐增长，且预后比HFREF更差［2］，然而目前尚无明确的诊断标准和治疗方法。本文旨在对HFPEF目前的研究进展进行综述。

Abstract:

Heart failure with preserved ejection fraction (HFPEF), formerly known as diastolic heart failure or heart failure with normal systolic function, is an increasing health problem. It is characterized by a normal or nearly normal left ventricular ejection fraction compared with HFREF, but with clinical manifestations of heart failure. The 2013 ACCF/AHA Guideline for the Management of Heart Failure has greatly improved the degree of attention to HFPEF. If left ventricular ejection fraction (LVEF) is ≥50%, it is defined as HFPEF. The incidence of this type increases gradually, and prognosis is poorer than for HFREF. However, there are no definite diagnostic standard and treatment methods. This paper mainly summarizes recent research of HFPEF.

参考文献/References

[1]Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2013,62(16):e147-239.
[2]Tribouilloy C,Rusinaru D,Mahjoub H,et al.Prognosis of heart failure with preserved ejection fraction:a 5 year prospective population-based study[J].Eur Heart J,2008,29(3):339-347.
[3]郭继鸿.舒张性心衰的新理念[J].临床心电学杂志,2009,18(3):209-221.
[4]Fonarow GC,Stough WG,Abraham WT,et al.Characteristics,treatments,and outcomes of patients with preserved systolic function hospitalized for heart failure a report from the OPTIMIZE-HF Registry[J].J Am Coil Cardiol,2007,50(8):768-777.
[5]Zile MR,Gottdiener JS,Hetzel SJ,et al.Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction[J].Circulation,2011,124(23):2491-501.
[6]Frangogiannis NG.The inflammatory response in myocardial injury,repair, and remodelling[J].Nat Rev Cardiol, 2014,11(5):255-265.
[7]McMurray JJ,Adamopoulos S,Anker SD,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association(HFA)of the ESC[J].Eur J Heart Fail,2012,14(8):803-869.
[8]Komajda M,Lam CS.Heart failure with preserved ejection fraction:a clinical dilemma[J].Eur Heart J,2014,35(16):1022-1032.
[9]Gaggin HK,Januzzi JL Jr.Biomarkers and diagnostics in heart failure[J].Biochim Biophys Acta,2013,1832(12):2442-2450.
[10]Tromp J,van der Pol A,Klip IT,et al.The Fibrosis Marker Syndecan-1 and Outcome in Heart Failure Patients with Reduced and Preserved Ejection Fraction[J].Circ Heart Fail,2014,7(3):457-462.
[11]Ewald B,Ewald D,Thakkinstian A,et al.Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction[J].Intern Med J,2008,38(2):101-113.
[12]Izumiya Y,Hanatani S,Kimura Y,et al.Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction[J].Can J Cardiol,2014, 30(3):338-344.
[13]Penicka M, Vanderheyden M, Bartunek J. Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography［J］. Heart, 2014, 100(1):68-76.
[14]Briggs J, Sutton M, Arstall M. A personalized exercise program for patients with both systolic and diastolic heart failure is associated with improved functional capacity and quality of life［J］. Heart Lung Circ, 2008, 17(Suppl):S148.
[15]Lund LH, Benson L, Dahlstrom U, et al. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction［J］. JAMA, 2012, 308(20):2108-2117.
[16]Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction［J］. N Engl J Med Overseas Ed, 2008, 359(23):2456-2467.
[17]Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial［J］. JAMA, 2013, 309(8): 781-791.
[18]Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction［J］. N Engl J Med, 2014, 370(15):1383-1392.
[19]Conraads VM, Metra M, Kamp O, et al. Effects of the long-termadministration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study［J］. Eur J Heart Fail, 2012, 14(2): 219-225.
[20]Athyros VG, Katsiki N, Karagiannis A. Treating heart failure with preserved ejection fraction: statins could make the difference［J］. Angiology, 2014, 65(4):328-329.
[21]Finegold JA1, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug?Systematic review of randomized placebo-controlled trials to aid individual patient choice［J］. Eur J Prev Cardiol, 2014, 21(4):464-474.
[22]Bondermann D, Pretsch I, Steringer-Mascherbauer R, et al. Acute Hemodynamic Effects of Riociguat in Patients with Pulmonary Hypertension Associated with Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study［J］. Chest, 2014, 146(5):1274-1285.
[23]Solomon SD, Zile M, Pieske B. Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysininhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial［J］. Lancet, 2012, 380(9851):1387-1395.
[24]Maier LS, Layug B, Karwatowska E. Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF Proof-of-Concept Study［J］. J Am Coll Cardiol Heart Failure, 2013, 1(2):115-122.
[25]KosmalaW, Holland DJ, Rojek A. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial［J］. J Am Coll Cardiol, 2013, 62(15):1330-1338.
[26]Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction:a randomized clinical trial[J].JAMA,2013,309(12):1268-1277.
[27]Filippatos G,Teerlink JR,Farmakis D,et al.Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial[J].Eur Heart J,2014,35(16):1041-1050.
[28]van Heerebeek L,Hamdani N,Falcao-Pires I,et al.Low myocardial protein kinase G activity in heart failure with preserved ejection fraction[J].Circulation,2012,126(7):830-839.
[29]Tribouilloy C,Rusinaru D,Mahjoub H,et al.Prognosis of heart failure with preserved ejection fraction:a 5 year prospective population-based study[J].Eur Heart J,2008,29(3):339-347.
[30]Wu CK,Lee JK,Chiang FT,et al.Prognostic factors of heart failure with preserved ejection fraction:a 12-year prospective cohort follow-up study[J].Int J Cardiol,2014,171(3):331-337.
[31]Zile MR,Gaasch WH,Anand IS,et al.I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial[J].Circulation,2010,121(12):1393-1405.
[32]Halley CM,Houghtaling PL,Khalil MK,et al.Mortality rate in patients with diastolic dysfunction and normal systolic function[J].Arch Intern Med,2011,171(12):1082-1087.

备注/Memo

备注/Memo:

收稿日期: 2014-06-10.
通讯作者：宁晓暄，副主任医师，主要从事老年内科疾病及老年多器官功能衰竭的临床和基础研究 Email:ningxx01@fmmu.edu.cn
作者简介：汪小素，硕士生 Email：869344789@qq.com

常用功能

更新日期/Last Update: 2015-07-23